Lilly's tabalumab dropped for RA, but lives on for lupus and multiple myeloma
This article was originally published in Scrip
Executive Summary
Eli Lilly's decision to discontinue development of tabalumab for the treatment of rheumatoid arthritis (RA) was not terribly surprising given the company's announcement in December that a Phase III RA clinical trial was terminated after an interim analysis due to a lack of efficacy (scripintelligence.com, 14 December 2012).